Sabadell - Sanofi (SAN) SANOFI: CMD - AIRE FRESCO (ANÃLISIS BANCO SABADELL)

Report

Sabadell

Oscar Rodriguez

EUR 200.00 For Business Accounts Only

SANOFI: CMD - AIRE FRESCO (ANÃLISIS BANCO SABADELL)

Anuncia un Plan EstratÃ©gico con fuertes mejoras operativas a largo plazo. COMPRAR
Ha anunciado las principales cifras de su Plan EstratÃ©gico (hoy celebra su CMD) donde prevÃ©n una importante aceleraciÃ³n del margen operativo hasta 30% en 2022 (vs 26,9% actual, 27,3% BS(e) y 28,5% consenso) y 32% en 2025 gracias a un plan de ahorro de costes de 2.000 M euros (20% EBITâ€™19) hasta 2022 y una apuesta clara por el crecimiento. En este sentido, SANO prevÃ© que Dupixent (principal blockbuster a largo plazo) alcance unas ventas pico de >10.000 M euros (vs ~2.000 M euros en 2019 y 4.790 M euros previsto a 2022) y que vacunas (16% ventas) crezca a un dÃgito medio-alto hasta 2025 (vs +6% previsto). AdemÃ¡s, separa CHC (primer paso para una eventual desinversiÃ³n). En definitiva, mensajes positivos que dadas las bajas perspectivas actuales en la compaÃ±Ãa podrÃan impulsar al valor tras un 2019 discreto (+8,2% en absoluto, -14% vs ES50).

10/12/2019 4 ES

Underlying

Sanofi

Sanofi is an integrated, global healthcare company focused on patient needs and engaged in the research, development, manufacture and marketing of healthcare products. Two segments make up Co.'s business: Pharmaceuticals and Vaccines. The Pharmaceuticals segment covers research, development, production and marketing of medicines, consisting of flagship products, plus a broad range of prescription medicines, generic medicines, and consumer health products. The Vaccines segment includes research, development, production and marketing of vaccines in five areas: pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines.

See profile

FR0000120578 Euronext Paris France

Provider

Sabadell

See profile

Analysts

Oscar Rodriguez

Other Reports on these Companies

GlobeNewsWire

Sanofi: Information concerning the total number of voting rights and shares - July 2025

Sanofi: Information concerning the total number of voting rights and shares - July 2025 Information concerning the total number of voting rights and shares, provided pursuant to article L. 233-8 II of the Code de commerce (the French Commercial Code) and article 223-16 of the Règlement général de l’Autorité des Marchés Financiers (Regulation of the French stock market authority) Sanofia French société anonyme with a registered share capital of €2,454,937,946Registered office : 46, avenue de la Grande Armée - 75017 Paris - FranceRegistered at the Paris Commercial and Companies Registry unde...

August 18, 2025 August 18, 2025 1 EN

GlobeNewsWire

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Juillet 2025

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Juillet 2025 Informations relatives au nombre total de droits de vote et d’actions prévues par l’article L. 233-8 II du Code de commerce et l’article 223-16 du Règlement général de l’Autorité des Marchés Financiers SanofiSociété anonyme au capital de 2 454 937 946 euros Siège social : 46, avenue de la Grande Armée - 75017 Paris395 030 844 R.C.S. Paris DateNombre d’actions composant le capital Nombre réel de droits de vote (déduction faite des actions auto-détenues)Nombre théorique de droits de vote (y compris actions...

August 18, 2025 August 18, 2025 1 EN

GlobeNewsWire

Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease

Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease Data from the positive Phase 2 study evaluating rilzabrutinib for the treatment of IgG4-related disease presented at EULAR 2025Additional orphan designation underscores Sanofi commitment to advancing new medicines in immune-mediated rare diseases Paris, August 14, 2025. The European Medicines Agency has granted orphan designation to rilzabrutinib, a reversible covalent Bruton’s tyrosine kinase (BTK) inhibitor, ...

August 14, 2025 August 14, 2025 1 EN

IBERIAN DAILY 22 AUGUST (ANÁLISIS BANCO SABADELL)

NEWS SUMMARY: IAG, TELEFÓNICA. Markets doubtful awaiting Powell in Jackson Hole European stock markets closed better than they opened, with some indices like the FTSE 100 managing to end with slight gains, whereas the DAX and IBEX ended practically flat. In the STOXX 600, the sectors rising the most were Energy, Banks and Basic Materials, with the biggest drops coming in Media, Consumer Goods and Chemicals. On the macro side, in the euro zone August’s preliminary manufacturing PMI rose more than expected, whereas the services index fell slightly, in line with expectations, and August’s consum...

EUR 100.00

August 22, 2025 August 22, 2025 1 EN

Research Department

Research Department

INFORME DIARIO 22 AGOSTO (ANÁLISIS BANCO SABADELL)

COMPAÑÍAS QUE APARECEN EN EL INFORME: ESPAÑA: IAG, TELEFÓNICA. EUROPA: AIR LIQUIDE. Mercados dubitativos a la espera de Powell en Jacson Hole Ayer las bolsas europeas fueron de menos a más y algunos índices como el FTSE 100 lograron terminar con ligeras ganancias mientras que el DAX y el Ibex terminaron casi sin cambios. En el STOXX 600 los sectores que más subieron fueron Energía, Bancos y R. Básicos frente a las mayores caídas de Media, B. Consumo y Químicas. Por el lado macro, en Eurozona el PMI manufacturero preliminar de agosto avanzó más de lo esperado mientras que el de Servicios retro...

EUR 100.00

August 22, 2025 August 22, 2025 1 ES

Research Department

Research Department

IBERIAN DAILY 21 AUGUST (ANÁLISIS BANCO SABADELL)

NEWS SUMMARY: N/A. IBEX hanging on and the FTSE 100 closes in positive numbers Yesterday European stock markets fell slightly, except the IBEX, which closed flat, and the FTSE 100, which rose +1.0%, while US tech stocks were once again punished by the doubts surrounding a possible AI bubble mentioned by S. Altman, CEO of OpenAI, over the past few days. In the STOXX 600, the sectors rising the most (by far) were Food and Household Products, with Construction and Travel & Leisure falling the most. On the macro side, in the euro zone July’s final general and core inflation confirmed the prelimin...

EUR 100.00

August 21, 2025 August 21, 2025 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

SANOFI: CMD - AIRE FRESCO (ANÃLISIS BANCO SABADELL)

Sanofi: Information concerning the total number of voting rights and shares - July 2025

Sanofi: Informations relatives au nombre de droits de vote et d'actions - Juillet 2025

Press Release: Sanofi’s rilzabrutinib earns orphan designation in the EU for IgG4-related disease

IBERIAN DAILY 22 AUGUST (ANÁLISIS BANCO SABADELL)

INFORME DIARIO 22 AGOSTO (ANÁLISIS BANCO SABADELL)

IBERIAN DAILY 21 AUGUST (ANÁLISIS BANCO SABADELL)

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe

SANOFI: CMD - AIRE FRESCO (ANÃLISIS BANCO SABADELL)